HC Deb 10 June 2002 vol 386 c1089W
Norman Baker

To ask the Secretary of State for Health what steps he takes to ensure, in the testing of drugs for potential carcinogenicity, commercial companies do not select animal species and strains of species where the incidence of carcinogenicity is low. [56017]

Ms Blears

[holding answer 14 May 2002]: The rationale for selecting species to be used in the carcinogenicity studies is stated in the guidance documents produced as a result of the International Conference of Harmonisation.